Acepodia, Inc. Stock

6976

KYG0073G1091

Biotechnology & Medical Research

End-of-day quote Taipei Exchange 04/09/2026			5-day change	1st Jan Change
12.10 ^TWD	+0.83%		+0.41%	-21.17%

09-04	Acepodia Receives FDA Clearance for Ind Application for ACE723, A Novel Dual-Payload Antibody-Drug Conjugate	CI
08-13	Acepodia, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Acepodia Inc is engaged in the research and development of new anti-cancer drugs. The Company uses antibody-cell conjugation (ACC) and immune cells. The products include Gamma delta 2T cell platform including ACE1831 (ACE-gdT-CD20) an antibody linked to specific target CD20 for treatment of lymphoma, ACE2016 (ACE-gdT-EGFR) an antibody linked to specific target EGFR , the target treatment of EGFR+ solid tumors, such as lung cancer, ACE1708 (ACE-gdT-PDL1) an antibody linked to the specific target PDL1 antibody, the target treatment of solid tumors; off-the-shelf natural killer (oNK) cell platform including ACE1702 (ACE-oNK-HER2) linked to a specific target HER2 antibody, targeting treatment of HER2+ solid tumors, such as breast cancer. The technologies include antibody cell linking technology, Gamma delta 2T cell screening, culture and amplification technology, oNK cell culture and amplification technology, Acepodia series of new cell drug preparations freezing and thawing technology.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
04/09/26	NT$12.10	+0.83%	363,847
03/09/26	NT$12.00	0.00%	417,466
02/09/26	NT$12.00	+0.42%	480,112
01/09/26	NT$11.95	0.00%	220,205
31/08/26	NT$11.95	-0.83%	367,006

End-of-day quote Taipei Exchange

More quotes

Stock Market
Stocks
6976 Stock

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	7.05B 223M 192M 180M 165M 308M 21.05B 309M 2.13B 828M 10.8B 837M 819M 34.79B	P/E 2024	-20x	P/E 2025	-11.8x
Enterprise Value	3.51B 111M 95.5M 89.85M 82.08M 154M 10.48B 154M 1.06B 412M 5.38B 417M 408M 17.32B	EV / Sales 2024	9,735,924,522x	EV / Sales 2025	29,160,315,200x
Free-Float	100%	Yield 2024 *	-	Yield 2025	-

09-04	Acepodia Receives FDA Clearance for Ind Application for ACE723, A Novel Dual-Payload Antibody-Drug Conjugate	CI
08-13	Acepodia, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-13	Acepodia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-25	Acepodia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-09	Biocytogen Pharmaceuticals Co., Ltd. and AcePodia Expand Collaboration Through Option-Based Evaluation Framework for First-In-Class Bispecific and Dual-Payload ADCs	CI
13/08/25	Acepodia, Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
28/05/25	Acepodia and Pfizer To Terminate Cooperation in Autoimmune Diseases Drugs Development	RE
28/05/25	AcePodia, Inc. Provides Update on Collaboration Under the Pfizer Ignite Program	CI
28/05/25	Acepodia, Inc. Announces CFO Changes, Effective from May 28, 2025	CI
28/05/25	Taiyo Yuden Co., Ltd. Announces Executive Changes, Effective from May 28, 2025	CI
19/03/25	Acepodia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
17/02/25	AcePodia Biotech, Inc. Announces Clearance of the IND by the Taiwan Food and Drug Administration for Investigational Product ACE2016	CI
08/01/25	Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors	CI

1 day	+0.83%
1 week	+0.41%
Current month	+1.26%
1 month	-2.02%
3 months	-6.56%
6 months	-5.10%
Current year	-21.17%

1 week	11.65	12.15
1 month	11.4	12.35
Current year	10.85	15.75
1 year	10.85	18.6
3 years	10.85	40.4
5 years	10.85	65
10 years	10.85	65

Manager	Title	Age	Since
Sonny Hsiao CEO	Chief Executive Officer	-	15/02/2017
Yan Ta Lai DFI	Director of Finance/CFO	-	01/04/2017
Lapyuen Lam CTO	Chief Tech/Sci/R&D Officer	68	01/04/2022

Acepodia, Inc. Stock

Stocks

6976

KYG0073G1091

Biotechnology & Medical Research

Valuation : Acepodia, Inc.

Chart: Acepodia, Inc.

Latest news : Acepodia, Inc.

Press Releases : Acepodia, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Acepodia, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Director	Title	Age	Since
Patrick Yang CHM	Chairman	78	15/02/2017
Sonny Hsiao BRD	Director/Board Member	-	15/02/2017
Samuel Chen BRD	Director/Board Member	75	14/10/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACEPODIA, INC.	+0.83%	+0.41%	-25.99%	-64.25%	223M
LONZA GROUP AG	-2.54%	-2.84%	-1.90%	+14.52%	48.93B
REVOLUTION MEDICINES, INC.	-0.40%	+1.03%	+439.20%	+499.20%	45.01B
IQVIA HOLDINGS INC.	-1.42%	+2.30%	+45.46%	+19.36%	44.07B
BEONE MEDICINES AG	-1.22%	-2.31%	+12.40%	+71.48%	40.73B
CELLTRION, INC.	+0.53%	-1.36%	+16.04%	+48.23%	33.52B
ASCENDIS PHARMA A/S	-0.21%	+9.14%	-	-	17.77B
MEDPACE HOLDINGS, INC.	-0.35%	-1.56%	+22.59%	+116.19%	16.5B
EUROFINS SCIENTIFIC SE	-1.01%	+0.50%	+15.83%	+27.98%	14.67B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.65%	-1.03%	+77.75%	+37.63%	13.77B
Average	-0.74%	+0.61%	+66.82%	+85.59%	27.52B
Weighted average by Cap.	-1.03%	+0.11%	+94.76%	+121.95%

	2024	2025
Net sales	0.43 0.01 0.01 0.01 0.01 0.02 1.27 0.02 0.13 0.05 0.65 0.05 0.05 2.11	0.18 0.01 0.01 0 0 0.01 0.55 0.01 0.06 0.02 0.28 0.02 0.02 0.91
Net income	-497M -15.7M -13.51M -12.71M -11.61M -21.72M -1.48B -21.78M -150M -58.29M -761M -58.96M -57.67M -2.45B	-754M -23.84M -20.52M -19.3M -17.64M -32.99M -2.25B -33.08M -228M -88.52M -1.16B -89.54M -87.59M -3.72B
Net Debt	-5.82B -184M -158M -149M -136M -254M -17.37B -255M -1.76B -683M -8.91B -691M -676M -28.71B	-3.54B -112M -96.32M -90.62M -82.79M -155M -10.57B -155M -1.07B -416M -5.42B -420M -411M -17.47B